Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04598893Active Not Recruiting

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

Role: lead

NCT04424927Phase 2Completed

PRV-015 in Gluten-free Diet Non-responsive Celiac Disease

Role: lead

NCT05087628Phase 2Terminated

PRV-3279-2a Trial in Systemic Lupus

Role: lead

NCT04270942Phase 2Completed

At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

Role: lead

All 4 trials loaded